SEVENFACT® For Bleeding Events In Hemophilia With Inhibitors

Overview

About this study

The purpose of this study is to evaluate the safety of SEVENFACT® when used to treat bleeding events in participants with Hemophilia A or B with inhibitors either with or without prophylactic treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Have a diagnosis of hemophilia A or B with inhibitors.
  • Be 12 to 65 years of age, inclusive.
  • Be capable of understanding and willing to comply with the conditions of the protocol or have a legal guardian who is capable of understanding and complying with the conditions of the protocol.
  • Have read, understood, and documented written informed consent/assent.
  • Be able to provide medical evidence through prior medical history of previous inhibitor levels.
  • Be willing and able to use the ATHN mobile application or a paper diary to document BEs and medication usage.

Exclusion Criteria:

  • Have a disorder of hemostasis in addition to Hemophilia A or B.
  • Have a known or suspected intolerance or hypersensitivity to SEVENFACT® or its ingredients.
  • Have a known allergy or hypersensitivity to rabbits or rabbit proteins.
  • Pregnant or lactating.
  • Have had implantation of an investigational medical device within the prior 6 monthsAre receiving prophylactic treatment for bleeding with a drug or biologic that is not approved for this use by the FDAHave received an investigational drug within 30 days of the baseline visitHave an elective surgical procedure planned during the duration of their participation in the study.
  • Have any life-threatening disease, or other disease or condition which, in the investigator’s judgment, could pose a potential hazard to the patient or interfere with study participation or study outcome (e.g., a history of non-responsiveness to bypassing products or thromboembolic disease)* Should a participant require an unplanned surgery, the participant will not be withdrawn from the study unless the investigator deems it necessary. Instead, the participant will receive standard of care treatment as determined by the attending physician. If the participant is not withdrawn from the study, the participant’s participation in the study will be paused until the investigator feels it is safe for them to continue.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rajiv Pruthi, M.B.B.S.

Closed for enrollment

Contact information:

Rajiv Pruthi

pruthi.rajiv@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20525293

Mayo Clinic Footer